Is Saakshi Medtech overvalued or undervalued?

As of 22 August 2025, the valuation grade for Saakshi Medtech has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company remains overvalued based on its current metrics. The PE ratio stands at 72.10, significantly higher than peers like Tata Chemicals at 53.91 and Kirloskar Industries at 26.49, both of which are categorized as attractive. Additionally, the EV to EBITDA ratio for Saakshi is 33.18, which is also elevated compared to Tata Chemicals' 14.59.
Given these ratios and the overall market context, Saakshi Medtech is considered overvalued. The company's return over the past year has been -23.71%, contrasting sharply with the Sensex's modest gain of 0.24%, further supporting the notion that the stock may not be a favorable investment at its current price of 191.95.